Grufity logo
Grufity logo
KTRA

KTRA - Kintara Therapeutics, Inc. Stock Price, Fair Value and News

$2.14 
Market Closed as of 03 Jun 2026, 04:00 pm ET

11/100

KTRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

KTRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KTRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KTRA Price Action

Last 7 days

-9.6%

Last 30 days

7.6%

Last 90 days

35.3%

Trailing 12 Months

-28.9%

KTRA RSI Chart

KTRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KTRA Valuation

Market Cap

136.1M

Price/Earnings (Trailing)

-4.4

Price/Sales (Trailing)

190.69

EV/EBITDA

-4.51

Price/Free Cashflow

-4.97

KTRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KTRA Fundamentals

KTRA Revenue

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

KTRA Earnings

Earnings (TTM)

-30.9M

Earnings Growth (Yr)

-13.12%

Earnings Growth (Qtr)

-11.5%

KTRA Profitability

EBT Margin

-4211.86%

Return on Equity

-133.36%

Return on Assets

-104.11%

Free Cashflow Yield

-20.11%

KTRA Investor Care

Shares Dilution (1Y)

45.55%

Diluted EPS (TTM)

-0.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025221.6K385.6K549.5K713.5K
2024---57.6K
2023---89.7K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Kintara Therapeutics, Inc.

KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
 CEO
 WEBSITEkintara.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3

Kintara Therapeutics, Inc. Frequently Asked Questions

KTRA is the stock ticker symbol of Kintara Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jun 03 2026, market cap of Kintara Therapeutics, Inc. is 136.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jun 03 2026, KTRA's PE ratio (Price to Earnings) is -4.4 and Price to Sales (PS) ratio is 190.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTRA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Kintara Therapeutics, Inc. has provided -0.66 (multiply by 100 for percentage) rate of return.